These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2234250)

  • 1. Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
    Chan MK
    Nephron; 1990; 56(1):56-61. PubMed ID: 2234250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease.
    Kanbay M; Bavbek N; Delibasi T; Koca C; Kaya A; Altay M; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2007; 29(3):309-13. PubMed ID: 17497445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient.
    Panuccio V; Enia G; Parlongo S; Cutrupi S; Zoccali C
    Nephron; 1996; 73(4):736. PubMed ID: 8856294
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
    Zwolińska D; Szprynger K
    Przegl Lek; 1997; 54(5):320-3. PubMed ID: 9380806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
    Yang KC; Fang CC; Su TC; Lee YT
    Am J Kidney Dis; 2005 Mar; 45(3):e57-60. PubMed ID: 15754265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body composition and lipid abnormalities in hispanic and black patients on continuous ambulatory peritoneal dialysis.
    Henriquez MA; Gonzalez A; Bemis JA; Esquivel J
    Perit Dial Int; 1993; 13 Suppl 2():S424-7. PubMed ID: 8399630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.
    Grützmacher P; Scheuermann EH; Siede W; Lang PD; Abshagen U; Radtke HW; Baldamus CA; Schoeppe W
    Klin Wochenschr; 1986 Oct; 64(19):910-6. PubMed ID: 3784441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the prostaglandin E1 analog enisoprost on glucose and lipid metabolism in patients with type II diabetes mellitus.
    Kasim SE; Moran M; Khilnani S; West MA; Jen KL
    Horm Metab Res; 1992 Apr; 24(4):176-80. PubMed ID: 1601393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J; Schwartz S; Brunner D
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
    Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia.
    Avogaro P; Bittolo Bon G; Cazzolato G; Soldan S; Bufalino L
    Drugs Exp Clin Res; 1989; 15(6-7):325-33. PubMed ID: 2686956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
    Ishiwata S; Nakanishi S; Nishiyama S; Seki A
    Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in lipid profiles in non diabetic, non nephrotic patients commencing continuous ambulatory peritoneal dialysis.
    O'Riordan E; O'Donoghue DJ; Kalra PA; Foley RN; Waldek S
    Adv Perit Dial; 2000; 16():313-6. PubMed ID: 11045318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.